ZACKS·2026-02-26 16:01Core Insights - Zai Lab Limited reported a revenue of $127.6 million for the quarter ended December 2025, reflecting a 17% increase year-over-year and a surprise of +6.85% over the Zacks Consensus Estimate of $119.42 million [1] - The company's EPS was -$0.46, an improvement from -$0.80 in the same quarter last year, although it was a -4.55% miss compared to the consensus estimate of -$0.44 [1] Revenue Breakdown - Total Product Revenue was $127.09 million, slightly below the average estimate of $132.11 million from three analysts [4] - Revenue from XACDURO was $10.7 million, exceeding the two-analyst average estimate of $9.6 million [4] - VYVGART generated $21.9 million, significantly lower than the average estimate of $39.74 million, representing a year-over-year decline of -27% [4] - NUZYRA reported $16 million, which is a +45.5% increase compared to the year-ago quarter, but below the average estimate of $17.22 million [4] - Collaboration revenue was $0.51 million, falling short of the average estimate of $19.34 million from two analysts [4] - ZEJULA achieved $56 million in revenue, surpassing the average estimate of $49.17 million and showing a year-over-year increase of +15.7% [4] Stock Performance - Zai Lab Limited's shares have returned +12.7% over the past month, outperforming the Zacks S&P 500 composite, which saw a +0.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]